Form 8-K - Current report:
SEC Accession No. 0001615219-22-000081
Filing Date
2022-05-12
Accepted
2022-05-12 16:14:06
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K flks-20220512.htm   iXBRL 8-K 35859
2 EX-99.1 salarius-earningsrelease1q.htm EX-99.1 62229
6 image_0.jpg GRAPHIC 111465
  Complete submission text file 0001615219-22-000081.txt   391940

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT flks-20220512.xsd EX-101.SCH 1930
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT flks-20220512_lab.xml EX-101.LAB 23984
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT flks-20220512_pre.xml EX-101.PRE 12633
8 EXTRACTED XBRL INSTANCE DOCUMENT flks-20220512_htm.xml XML 11339
Mailing Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 346-772-0346
Salarius Pharmaceuticals, Inc. (Filer) CIK: 0001615219 (see all company filings)

EIN.: 465087339 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36812 | Film No.: 22917957
SIC: 2834 Pharmaceutical Preparations